Skip to main content
Erschienen in: Documenta Ophthalmologica 1/2013

01.02.2013 | Clinical Case Report

Persistence of retinal function after intravitreal melphalan injection for retinoblastoma

verfasst von: Scott E. Brodie, Francis L. Munier, Jasmine H. Francis, Brian Marr, Y. Pierre Gobin, David H. Abramson

Erschienen in: Documenta Ophthalmologica | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The risk/benefit profile of intravitreal melphalan injection for treatment of active vitreous seeds in retinoblastoma remains uncertain. We report clinical and electroretinography results after 6 months of one patient who has shown a favorable initial clinical response to intravitreal melphalan injections for treatment of refractory vitreous seeds.

Methods

Clinical case report.

Patient

The patient presented at age 17 months with bilateral retinoblastoma [OD: International Classification (ICRB) group E, Reese-Ellsworth (R-E) class Vb; OS: ICRB D, R-E Vb] with no known prior family history. The right eye was enucleated primarily. The patient received systemic chemotherapy and extensive local treatment to the left eye. Ten months later, she presented with recurrent disease, including fine, diffuse vitreous seeds. Tumor control was established with intra-arterial chemotherapy and local treatment. Subsequent recurrence was treated with further intra-arterial chemotherapy, local treatment, and plaque radiotherapy with iodine-125. Persistent free-floating spherical vitreous seeds were treated with 4 cycles of intravitreal melphalan injection via the pars plana, with doses of 30, 30, 30, and 20 μg.

Results

After 6 months of follow-up, the left eye remained free of active tumor. Visual acuity was 20/40. Photopic ERGs amplitudes were unchanged compared with those recorded prior to the intravitreal injection treatments.

Conclusions

Intravitreal melphalan injection for refractory spherical vitreous seeds of retinoblastoma with favorable tumor response is compatible with good central visual acuity and preservation of retinal function as indicated by photopic ERG recordings.
Literatur
1.
Zurück zum Zitat Abramson DH, Marr BP, Dunkel IJ, Brodie S, Zabor EC, Driscoll SJ, Gobin YP (2012) Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 96(4):499–502PubMedCrossRef Abramson DH, Marr BP, Dunkel IJ, Brodie S, Zabor EC, Driscoll SJ, Gobin YP (2012) Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 96(4):499–502PubMedCrossRef
2.
Zurück zum Zitat Seregards S, Singh AD (2012) Retinoblastoma: direct chemotherapeutic drug delivery into the vitreous cavity. Br J Ophthalmol 96(4):473–474CrossRef Seregards S, Singh AD (2012) Retinoblastoma: direct chemotherapeutic drug delivery into the vitreous cavity. Br J Ophthalmol 96(4):473–474CrossRef
3.
Zurück zum Zitat Boon CJF, Crama N, Klevering J, van Kuijk FJ, Hoyng C (2008) Reflux after intravitreal injection of bevacizumab. Ophthalmology 115(7):1270PubMedCrossRef Boon CJF, Crama N, Klevering J, van Kuijk FJ, Hoyng C (2008) Reflux after intravitreal injection of bevacizumab. Ophthalmology 115(7):1270PubMedCrossRef
4.
Zurück zum Zitat Hodjatjalali K, Riazi M, Faghihi H, Khorami A (2012) Ultrasound biomicroscopy study of vitreous incarceration subsequent to intravitreal injections. Can J Ophthalmol 47(1):24–27PubMed Hodjatjalali K, Riazi M, Faghihi H, Khorami A (2012) Ultrasound biomicroscopy study of vitreous incarceration subsequent to intravitreal injections. Can J Ophthalmol 47(1):24–27PubMed
5.
Zurück zum Zitat Ueda M, Tanabe J, Suzuki T, Sakay H, Mochizuki K, Kitano K, Inomata M, Kaneko A (1994) Conservative therapy for retinoblastoma—effect of melphalan on in vitro electroretinogram. Nihon Ganka Gakkai Zasshi 98(4):352–356PubMed Ueda M, Tanabe J, Suzuki T, Sakay H, Mochizuki K, Kitano K, Inomata M, Kaneko A (1994) Conservative therapy for retinoblastoma—effect of melphalan on in vitro electroretinogram. Nihon Ganka Gakkai Zasshi 98(4):352–356PubMed
6.
Zurück zum Zitat Ueda M, Tanabe J, Inomata M, Kaneko A, Kimura T (1995) Study on conservative treatment of retinoblastoma—effect of intravitreal injection of melphalan on the rabbit retina. Nihon Ganka Gakkai Zasshi 99(11):1230–1235PubMed Ueda M, Tanabe J, Inomata M, Kaneko A, Kimura T (1995) Study on conservative treatment of retinoblastoma—effect of intravitreal injection of melphalan on the rabbit retina. Nihon Ganka Gakkai Zasshi 99(11):1230–1235PubMed
7.
Zurück zum Zitat Kivela T, Eskelin S, Paloheimo M (2011) Intravitreal methotrexate for retinoblastoma. Ophthalmology 118(8):1689PubMedCrossRef Kivela T, Eskelin S, Paloheimo M (2011) Intravitreal methotrexate for retinoblastoma. Ophthalmology 118(8):1689PubMedCrossRef
8.
Zurück zum Zitat Smith SJ, Pulido JS, Salomao DR, Smith BD, Mohney B (2012) Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds. Br J Ophthalmol 96:1073–1077PubMedCrossRef Smith SJ, Pulido JS, Salomao DR, Smith BD, Mohney B (2012) Combined intravitreal and subconjunctival carboplatin for retinoblastoma with vitreous seeds. Br J Ophthalmol 96:1073–1077PubMedCrossRef
9.
Zurück zum Zitat Munier FL, Soliman S, Moulin AP, Gaillard M-C, Balmer A, Beck-Popovic M (2012) Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilization of the needle track. Br J Ophthalmol 96:1084–1087PubMedCrossRef Munier FL, Soliman S, Moulin AP, Gaillard M-C, Balmer A, Beck-Popovic M (2012) Profiling safety of intravitreal injections for retinoblastoma using an anti-reflux procedure and sterilization of the needle track. Br J Ophthalmol 96:1084–1087PubMedCrossRef
10.
Zurück zum Zitat Munier FL, Gaillard M-C, Balmer A, Soliman S, Podilsky G, Moulin AP, Beck-Popovic M (2012) Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 96:1078–1083PubMedCrossRef Munier FL, Gaillard M-C, Balmer A, Soliman S, Podilsky G, Moulin AP, Beck-Popovic M (2012) Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 96:1078–1083PubMedCrossRef
11.
Zurück zum Zitat Brodie SE, Gobin YP, Dunkel IJ, Kim JW, Abramson DH (2009) Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol 119(1):13–22PubMedCrossRef Brodie SE, Gobin YP, Dunkel IJ, Kim JW, Abramson DH (2009) Persistence of retinal function after selective ophthalmic artery chemotherapy infusion for retinoblastoma. Doc Ophthalmol 119(1):13–22PubMedCrossRef
12.
Zurück zum Zitat Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M (2009) Standard for clinical electroretinography (2008 update). Doc Ophthalmol 118:69–77PubMedCrossRef Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M (2009) Standard for clinical electroretinography (2008 update). Doc Ophthalmol 118:69–77PubMedCrossRef
Metadaten
Titel
Persistence of retinal function after intravitreal melphalan injection for retinoblastoma
verfasst von
Scott E. Brodie
Francis L. Munier
Jasmine H. Francis
Brian Marr
Y. Pierre Gobin
David H. Abramson
Publikationsdatum
01.02.2013
Verlag
Springer-Verlag
Erschienen in
Documenta Ophthalmologica / Ausgabe 1/2013
Print ISSN: 0012-4486
Elektronische ISSN: 1573-2622
DOI
https://doi.org/10.1007/s10633-012-9358-6

Weitere Artikel der Ausgabe 1/2013

Documenta Ophthalmologica 1/2013 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Open Access 22.02.2024 | Peeling | Originalien

Selektive Vitalfarbstoffe in der Makulachirurgie

Erhöhen sie die Wahrscheinlichkeit der intraoperativen ILM-Identifizierung auch bei einem erfahrenen Operateur?

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.